UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism

Cancer research (Chicago, Ill.), 2014-06, Vol.74 (12), p.3317-3331

2014

Volltextzugriff (PDF)

Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer

Molecular cancer therapeutics, 2011-05, Vol.10 (5), p.817-824

2011

Volltextzugriff (PDF)

Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion

Proceedings of the National Academy of Sciences - PNAS, 2007-02, Vol.104 (9), p.3261-3266

2007

Volltextzugriff (PDF)

620 Tumor cell-intrinsic STING pathway is activated in the presence of cues from immune cells and contributes to the anti-tumor activity of tumor cell-targeted STING agonist antibody-drug conjugates

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A373-A373

2020

Volltextzugriff (PDF)

Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies

Oncogene, 2016-11, Vol.35 (47), p.6077-6086

2016

Volltextzugriff (PDF)

Abstract 1773: Tumor cell-intrinsic STING pathway activation leads to robust induction of Type III Interferons and contributes to the anti-tumor activity elicited by STING agonism

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1773-1773

2021

Volltextzugriff (PDF)

The Business of Sustainable Tourism Development and Management

1st edition., 2020

Volltextzugriff (PDF)

Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor

ACS medicinal chemistry letters, 2017-10, Vol.8 (10), p.1116-1121

2017

Volltextzugriff (PDF)

Abstract 907: XMT-1660, a B7-H4-targeted Dolasynthen antibody-drug conjugate for the treatment of breast cancer

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.907-907

2021

Volltextzugriff (PDF)

Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1738-1738

2021

Volltextzugriff (PDF)

Abstract P167: Site-specific Dolasynthen ADCs demonstrate consistent exposure across a wide range of drug-to-antibody ratios

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P167-P167

2021

Volltextzugriff (PDF)

Abstract 2894: XMT-1592, a site-specific Dolasynthen-based NaPi2b-targeted antibody-drug conjugate for the treatment of ovarian cancer and lung adenocarcinoma

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.2894-2894

2020

Volltextzugriff (PDF)

Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.6706-6706

2020

Volltextzugriff (PDF)

Synthetic Silvestrol Analogues as Potent and Selective Protein Synthesis Inhibitors

Journal of medicinal chemistry, 2012-10, Vol.55 (20), p.8859-8878

2012

Volltextzugriff (PDF)

Optimization of 3‑Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1

ACS medicinal chemistry letters, 2017-02, Vol.8 (2), p.151-156

2017

Volltextzugriff (PDF)

Hsp90 (Heat Shock Protein 90) Inhibitor Occupancy Is a Direct Determinant of Client Protein Degradation and Tumor Growth Arrest in Vivo

The Journal of biological chemistry, 2010-12, Vol.285 (51), p.39835-39843

2010

Volltextzugriff (PDF)

Optimization of 3‑Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors

ACS medicinal chemistry letters, 2018-07, Vol.9 (7), p.746-751

2018

Volltextzugriff (PDF)

Abstract A144: Inhibition of 2-HG production in IDH mutant xenograft models

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.A144-A144

2013

Volltextzugriff (PDF)

Abstract 1601: Hsp90 inhibition results in a significant delay in tumor progression in a model of emerging EGFR TKI resistance in non-small cell lung cancer

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.1601-1601

2011

Volltextzugriff (PDF)

Abstract LB-139: IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.LB-139-LB-139

2014

Volltextzugriff (PDF)

Abstract A215: Hsp90 inhibitor IPI-504 demonstrates antitumor activity against a panel of neuroendocrine/carcinoid cell lines in vitro and in vivo

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.A215-A215

2009

Volltextzugriff (PDF)

Memories of Mary Appelhof 1936-2005

BioCycle, 2005-08, Vol.46 (8), p.22-22

Young, Michele

2005

Volltextzugriff (PDF)

Staying InformED: Top emergency Medicine pharmacotherapy articles of 2020

The American journal of emergency medicine, 2021-11, Vol.49, p.200-205

2021

Volltextzugriff (PDF)

From Isolation to Connection: The Practices and Promise of Open Domestic Violence Shelters

Journal of interpersonal violence, 2022-05, Vol.37 (9-10), p.NP7315-NP7342

2022

Volltextzugriff (PDF)

Key articles and guidelines for the emergency medicine clinical pharmacist: 2011-2018 update

American journal of health-system pharmacy, 2020-08, Vol.77 (16), p.1284-1335

2020

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(47)

Publikationsform

Sprache

Englisch
(49)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Life Sciences & Biomedicine
(15)
Humans
(12)
Animals
(6)
Female
(6)
Mice
(6)
Pharmacology & Pharmacy
(6)
Antineoplastic Agents - Pharmacology
(5)
Chemistry, Medicinal
(4)
Oncology
(4)
Tumors
(4)
Xenograft Model Antitumor Assays
(4)
60 Applied Life Sciences
(3)
Cell Line, Tumor
(3)
Letter
(3)
Adult
(2)
Aged
(2)
Anti-Bacterial Agents - Therapeutic Use
(2)
Antibodies, Monoclonal - Pharmacology
(2)
Antineoplastic Agents - Pharmacokinetics
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism

Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer

Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion

620 Tumor cell-intrinsic STING pathway is activated in the presence of cues from immune cells and contributes to the anti-tumor activity of tumor cell-targeted STING agonist antibody-drug conjugates

Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies

Abstract 1773: Tumor cell-intrinsic STING pathway activation leads to robust induction of Type III Interferons and contributes to the anti-tumor activity elicited by STING agonism

The Business of Sustainable Tourism Development and Management

Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor

Abstract 907: XMT-1660, a B7-H4-targeted Dolasynthen antibody-drug conjugate for the treatment of breast cancer

Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity

Abstract P167: Site-specific Dolasynthen ADCs demonstrate consistent exposure across a wide range of drug-to-antibody ratios

Abstract 2894: XMT-1592, a site-specific Dolasynthen-based NaPi2b-targeted antibody-drug conjugate for the treatment of ovarian cancer and lung adenocarcinoma

Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines

Synthetic Silvestrol Analogues as Potent and Selective Protein Synthesis Inhibitors

Optimization of 3‑Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1

Hsp90 (Heat Shock Protein 90) Inhibitor Occupancy Is a Direct Determinant of Client Protein Degradation and Tumor Growth Arrest in Vivo

Optimization of 3‑Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors

Abstract A144: Inhibition of 2-HG production in IDH mutant xenograft models

Abstract 1601: Hsp90 inhibition results in a significant delay in tumor progression in a model of emerging EGFR TKI resistance in non-small cell lung cancer

Abstract LB-139: IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism

Abstract A215: Hsp90 inhibitor IPI-504 demonstrates antitumor activity against a panel of neuroendocrine/carcinoid cell lines in vitro and in vivo

Memories of Mary Appelhof 1936-2005

Staying InformED: Top emergency Medicine pharmacotherapy articles of 2020

From Isolation to Connection: The Practices and Promise of Open Domestic Violence Shelters

Key articles and guidelines for the emergency medicine clinical pharmacist: 2011-2018 update

Suchergebnisse filtern